OTHER NEWS - Nov. 12, 1994
From Times Staff and Wire Reports
ICN Merger Complete: Costa Mesa-based ICN Pharmaceuticals Inc. said Friday that it has completed its merger with three affiliated corporations: SPI Pharmaceuticals, ICN Biomedicals and Viratek. Each share of pre-merger ICN Pharmaceuticals stock will be converted to 0.512 share of new ICN common stock. Each share of SPI stock will be converted to a full share of new ICN common stock. Viratek shares will be converted at the rate of one for each 0.499 share of new ICN, and each share of ICN Biomedicals will convert to 0.197 share of new ICN. Separately, ICN said Friday that it has acquired from Fujisawa USA Inc. the rights to develop and commercialize a group of compounds related to and including Human Growth Hormone Releasing Factor.
